share_log

里昂:上调药明康德目标价至92.4港元 列为内地CRO板块首选

Citi has raised the Target Price of WUXI APPTEC to HKD 92.4 and listed it as the top choice in the Mainland CRO Sector.

Breakings ·  Mar 18 06:48

Citi's research report states that WUXI APPTEC's adjusted Net income in the fourth quarter of last year was in line with expectations, and Order growth exceeded expectations. The company expects to maintain a year-on-year revenue increase of 10% to 15% this year, and the adjusted Net income margin will further improve. The company also expects capital expenditures this year to reach 7 billion to 8 billion yuan, mainly for expanding production capacity in China, the USA, and Singapore, and additionally recommends repurchasing 1 billion yuan of A shares. The bank has raised its Net income forecast for WUXI APPTEC for this year and next by 0% to 1%, increasing the Target Price for Listed in Hong Kong from HKD 73.6 to HKD 92.4, while reiterating the 'outperforming the market' rating and listing it as the top choice in the Mainland CRO Sector.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Comment Comment · Views 302

Recommended

Write a comment

Statement

This page is machine-translated. Futubull tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.